# Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

> **NCT06518018** · — · ACTIVE_NOT_RECRUITING · sponsor: **The First People's Hospital of Neijiang** · enrollment: 80 (estimated)

## Conditions studied

- Advanced Stage NSCLC
- Second-line Treatment
- Patients Without Targetable Driver Mutations

## Interventions

- **RADIATION:** HDR brachytherapy (30Gy single fraction)
- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT06518018
- **Lead sponsor:** The First People's Hospital of Neijiang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06518018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06518018, "Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06518018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*